trump glp-1 prices From Most Expensive to Most Favored: How the Administration Is Bringing Down Prescription Drug KFF Health Tracking Poll: Prescription

The growing patient numbers directly lead to higher adoption rates, encouraging pharmaceutical companies to scale production and innovate within this segment to meet expanding clinical needs

AAIC 2026 A comparative effectiveness analysis of second-line diabetes medications in realworld registry (Danish registry) comparing GLP-1 RAs to other agents found a protective effect of GLP-1 RAs vs certain other second-line drugs over 5 years, though not against all comparators

extensive post-market safety data

The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis

GPs are being encouraged to talk to patients about the safety of unapproved weight-loss medications, following new concerns over unregistered GLP-1 products being promoted online